FdaApplication
BLA 019717
Identifiers
- fda_app_no: BLA019717
Properties
| Property | Value |
|---|---|
| applicant_name | Eli Lilly and Company |
| application_type | BLA |
| approval_date | 1989-04-25 |
Revenue by product
HUMULIN 70/30
| Period | Revenue |
|---|---|
| Q4 2024 | $280.3M |
| Q3 2024 | $207.1M |
| Q2 2024 | $223.6M |
| Q1 2024 | $206.2M |
| Q4 2023 | $188.1M |
| Q3 2023 | $206.7M |
| Q2 2023 | $205.3M |
| Q1 2023 | $252.0M |
| Q4 2022 | $234.0M |
| Q3 2022 | $238.2M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
HUMULIN 70/30 PEN
| Period | Revenue |
|---|---|
| Q4 2024 | $280.3M |
| Q3 2024 | $207.1M |
| Q2 2024 | $223.6M |
| Q1 2024 | $206.2M |
| Q4 2023 | $188.1M |
| Q3 2023 | $206.7M |
| Q2 2023 | $205.3M |
| Q1 2023 | $252.0M |
| Q4 2022 | $234.0M |
| Q3 2022 | $238.2M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
HUMULIN 70/30
| Period | Revenue |
|---|---|
| Q4 2024 | $280.3M |
| Q3 2024 | $207.1M |
| Q2 2024 | $223.6M |
| Q1 2024 | $206.2M |
| Q4 2023 | $188.1M |
| Q3 2023 | $206.7M |
| Q2 2023 | $205.3M |
| Q1 2023 | $252.0M |
| Q4 2022 | $234.0M |
| Q3 2022 | $238.2M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (3)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| HUMULIN 70/30 | INSULIN RECOMBINANT HUMAN; INSULIN SUSP ISOPHANE RECOMBINANT HUMAN | 700UNITS/10ML (70UNITS/ML); 300UNITS/10ML (30UNITS/ML) | Injectable Suspension |
| HUMULIN 70/30 | INSULIN RECOMBINANT HUMAN; INSULIN SUSP ISOPHANE RECOMBINANT HUMAN | 210UNITS/3ML (70UNITS/ML); 90UNITS/3ML (30UNITS/ML) | Injectable Suspension |
| HUMULIN 70/30 | — | 210UNITS/3ML (70UNITS/ML); 90UNITS/3ML (30UNITS/ML) | Injectable Suspension |
3 products